Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

New MMR Vaccine Information Statement.

[No authors listed]

Mich Med. 2012 Jul-Aug;111(4):21. No abstract available.

PMID:
23252144
3.
4.

Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.

Pediatr Infect Dis J. 2005 Dec;24(12):1083-8.

PMID:
16371870
5.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
7.
8.

Mumps, measles and rubella vaccination: a pragmatic study.

Sutton GC.

Public Health. 1991 Mar;105(2):133-8.

PMID:
2068236
9.

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E.

Vaccine. 2002 Jan 15;20(7-8):1134-40.

PMID:
11803074
10.

Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.

Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.

Pediatr Infect Dis J. 1999 Jan;18(1):42-8.

PMID:
9951979
11.

Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.

Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA.

Clin Immunol. 2005 May;115(2):154-61.

PMID:
15885638
13.

[Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].

Zäch K, Nicoara C, Germann D, Matter L.

Schweiz Med Wochenschr. 1998 Apr 25;128(17):649-57. German.

PMID:
9622837
14.

A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.

Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL.

Southeast Asian J Trop Med Public Health. 1999 Sep;30(3):511-7.

PMID:
10774661
15.

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.

Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, Cryz SJ Jr.

Vaccine. 1998 Jan-Feb;16(2-3):298-304.

PMID:
9607046
16.

Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.

Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF.

Vaccine. 2010 Jan 8;28(3):692-8. doi: 10.1016/j.vaccine.2009.10.083. Epub 2009 Oct 25.

PMID:
19861187
17.

Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.

Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.

Vaccine. 2009 Jan 14;27(3):446-53. doi: 10.1016/j.vaccine.2008.10.064. Epub 2008 Nov 11.

PMID:
19007835
18.
19.

The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad.

Pediatr Infect Dis J. 2006 Jul;25(7):615-22.

PMID:
16804432
20.

Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.

Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.

Vaccine. 2009 May 5;27(20):2701-6. doi: 10.1016/j.vaccine.2009.02.044. Epub 2009 Feb 24.

PMID:
19428882

Supplemental Content

Support Center